|Day Low/High||38.25 / 39.64|
|52 Wk Low/High||37.54 / 151.80|
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
Let's look at the cold, hard facts around the vaccine rollout.
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
Good stock picking continues as market participants shrug off a host of negatives.